FDA Issues First MoCRA Warning Letter

  • September 19, 2024
warning-letter-2022

The Modernization of Cosmetics Regulation Act (MoCRA) of 2022 represents a significant shift in how cosmetics are regulated in the United States. On June 12, 2024, the FDA issued a warning letter to Landy International, a pharmaceutical manufacturer with products that fall under the cosmetics category. The letter highlighted violations of Current Good Manufacturing Practice (CGMP) regulations and emphasized that MoCRA applies to Landy International’s cosmetic products. This incident serves as an important reminder for the entire cosmetics industry about the critical need to comply with MoCRA.

The FDA Warning letter, which essentially addresses CGMP violations related to Landy International's drug manufacturing, mentions MoCRA, which is particularly significant. It highlights the fact that even companies not exclusively focused on cosmetics must understand MoCRA's regulations if their products qualify as "cosmetic products" under FDA’s definition. The definition, found in 21 U.S.C. § 364(2) , defines a cosmetic product as "a preparation of cosmetic ingredients with a qualitatively and quantitatively set composition for use in a finished product". The definition covers a wide array of products, such as makeup, skincare, lotions, and shampoos, commonly found in the health and beauty sections.

Consequently, the Landy case serves as a warning for the cosmetics industry, emphasizing the need for proactive compliance with MoCRA to prevent regulatory issues, which may end up with a Warning Letter. MoCRA introduces a new phase in cosmetics regulation. By staying informed and ensuring compliance, companies can better secure their success in the constantly changing beauty market.

How Quantum Can Help

Since 1992 Quantum Analytics Group has been supporting cosmetics, beauty, and personal care product manufactures with testing and consulting services. Our services include consulting on cGMP standards and practices, product testing services to support quality and release testing, label reviews, quality audit support, and more.

Quantum provides comprehensive analytical testing in support of personal care products, cosmetics, beauty products, and consumer products. These include the testing of ingredients,raw materials, in-process samples and finished products.

Read the FDA Warning Letter

QUANTUM Analytics Group Solves Problems. Our approach is to work closely with each client collaboratively, handling every project with personal care, and giving every client one-on-one attention. Then, through this collaborative approach, and our unique blend of experience and expertise, we focus on providing accurate, efficient and consistent data and results to address and resolve questions or issues that impact your products.

For a Free Consultation Call 800-448-2968 to speak with one of our experts.

Blog Post

Related Articles

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

1,4-Dioxane: Facts, Insight and Compliance Strategies for Manufacturers Facing New Limits

November 3, 2025
Background The EPA has designated 1,4-dioxane as a suspected carcinogen. Consequently, New York regulations signed into...

Toxic Metals in Chocolate

July 11, 2024
Arsenic, cadmium, lead and mercury dominated the news last year when elevated levels were found in some batches of baby...

Nitrosamine Contamination: Potential Root Causes

July 11, 2024
The Formation of Nitrosamine Impurities in API and Finished Dosage Forms A discussion on potential root causes